Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 30c, Revenues Beat; Offers FY20 Revenue Guidance
Go back to Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 30c, Revenues Beat; Offers FY20 Revenue Guidance| JAZZ PHARMACEUTICAL (NASDAQ: JAZZ) | Delayed: 225.92 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $225.92 | 52 Week High | $160.00 | |||
| Open | $225.92 | 52 Week Low | $95.80 | |||
| Day High | $225.92 | P/E | 41.99 | |||
| Day Low | $225.92 | EPS | $5.38 | |||
| Volume | 1,202 | |||||
